Figure 2
From: Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy
Key qualities of KDM5A underscore its therapeutic potential in osteosarcoma. Overall, KDM5A likely regulates osteogenic differentiation through repression of multiple different pathways of differentiation signaling. Thus, KDM5A inhibition is an excellent novel candidate for RB−/− osteosarcoma targeted therapy.
